Sionna Therapeutics, Inc. (SION): Capital Expenditures
$377.0K
Year ended 2025-12-31
$291.0K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $377.0K | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $27.0K | n/a | 2026-03-02, From 2024-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $377.0K | n/m |
| Omeros Corp (OMER) | 2025-12-31 | $65.0K | -60.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
| Liquidia Corp (LQDA) | 2025-12-31 | $4.34M | -12.4% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $440.0K | -92.5% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $138.0K | -12.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $52.0K | -93.2% |
Compare SION, OMER, SPRY, LQDA side by side · Screen every company in Pharmaceutical Preparations ↗